7^th World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit August 29-31, 2016 Atlanta, Georgia, USA

Wael Talaat has completed his PhD from Faculty of Pharmacy, Mansoura University, Egypt. He is an Assistant Professor of Analytical Chemistry in Faculty of Pharmacy, Damanhour University, Egypt. He has published 6 papers in reputed journals and 2 US and WO patent applications.

A simple, reversed phase high performance liquid chromatographic method has been developed for the determination of lamivudine, indinavir and ketoconazole in pharmaceutical preparations, human plasma and urine. The method was conducted using a Shim-pack VP-ODS (150 X 4.6 mm I.D.) stainless steel column at ambient temperature with UV detection at 225 nm. Micellar mobile phase consisted of 0.07 M sodium dodecyl sulphate (SDS), 10% n-propanol, 0.3% triethylamine in 0.02 M phosphoric acid (pH 4.5) was used and pumped at a flow rate of 1.2 mL/min. The calibration curve was rectilinear over the concentration range of (0.05-1.0) µg /mL and (0.2–5.0) and (0.3–5.0) µg /mL lamivudine, indinavir and ketoconazole respectively. The proposed method was successfully applied to the analysis of these drugs in some dosage forms. The method was extended to the in-vitro, in-vivo determination of these drugs in spiked and real human plasma samples.

Oleksii Popov is an aspirant of the Department of Clinical Pharmacology and Clinical Pharmacy of the National University of Pharmacy, Ukraine with a number of articles published in reputed international and Ukrainian scientific journals.

Medication Diclocor is the original capsulated pharmaceutical composition which contains classical, non-steroid and anti-inflammatory drug diclofenac sodium and a lipoxygenase inhibiting bioflavonoid quercetin. Additionally, it possesses antioxidant, angioprotective, cardioprotective and other activity. The results of the conducted preclinical trials have proven that Diclocor obtains pronounced anti-inflammatory, analgesic, cardioprotective, and chondroprotective activity, which is higher than that of the known drugs like voltaren and quercetin. A prominent feature of this medication is a modifying influence of quercetin on pharmacological and toxicological properties of diclofenac sodium providing for a reduction of the effective dose of diclofenac sodium and, thus, for decrease in side effect incidence and rise of tolerability. It is possible that quercetin enhances bioavailability of diclofenac sodium leading to synergy in the form of potentiating or additive effect. Diclocor is recommended for phase I clinical trials and the suggested schemes are as follows: 1) For single dose tolerability study- 2 capsules (50 mg by diclofenac sodium) and 3 capsules (75 mg by diclofenac sodium); 2) for course dose tolerability study- 1 capsule 2 times a day (50 mg/day by diclofenac sodium) and 2 capsules 2 times a day (100 mg/day by diclofenac sodium). The optimal treatment course length is 7 days.